Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.
Edwards Lifesciences (EW) Gains on Innovation, Margin Growth
by Zacks Equity Research
In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.
LabCorp (LH) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 1.97% and 2.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Quest Diagnostics (DGX) New Pact to Boost Laboratory Services
by Zacks Equity Research
Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.
Thermo Fisher (TMO) Rides on Strong End Markets, New Launches
by Zacks Equity Research
Thermo Fisher's (TMO) newly-launched Gibco CTS DynaCellect Magnetic Separation System is helping customers advance their cell and gene therapy programs.
Charles River (CRL) Introduces Novel IgY-Based ELISA Kit
by Zacks Equity Research
Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.
ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
by Zacks Equity Research
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on continued partnership growth and a strong focus on strategic execution.
Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges
by Zacks Equity Research
At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.
BD's (BDX) Latest Combination Test Receives the FDA's EUA
by Zacks Equity Research
BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth
by Zacks Equity Research
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical
by Zacks Equity Research
McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.
5 Dental Supplies Stocks to Buy Amid Recovering Prospects
by Indrajit Bandyopadhyay
Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.
Hologic (HOLX) Q1 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Lower COVID-19 assays sales and supply chain challenges related to semiconductor chips dent Hologic's (HOLX) top line in Q1.
Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Robust year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments boost Thermo Fisher's (TMO) Q4 revenues.
Integer Holdings (ITGR) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.